BLA 761147 · Accord Biopharma Inc.
Ennumo
Pegfilgrastim-Pccg · Subcutaneous
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 7, 2026
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
400
72 Phase 3, 30 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast CancerPivotal-lookingActive, not recruiting
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyAcademic, hospital or other
NCT00433420 · 2,000 participants (planned) · Start Apr 2003 · Primary completion May 2006
Drug: pegfilgrastim; cyclophosphamide and 3 more · For: Breast Cancer
- TAC Versus TC for Adjuvant Breast CancerPivotal-lookingCompleted
US Oncology ResearchIndustry
NCT00493870 · 1,961 participants · Start May 29, 2007 · Primary completion May 31, 2015
Drug: Docetaxel; Doxorubicin and 1 more · For: Breast Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Sedona, Arizona · 95 sites in all
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00887536 · 1,613 participants · Start May 2009 · Primary completion Feb 2018
Drug: bevacizumab; docetaxel and 3 more · For: Breast Cancer
Sites: Bessemer, Alabama; Birmingham, Alabama; Huntsville, Alabama · 533 sites in all
- Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial CancerPivotal-lookingCompleted
GOG FoundationResearch network
NCT00063999 · 1,381 participants · Start Aug 25, 2003 · Primary completion Jun 29, 2013
Drug: Carboplatin; Cisplatin and 4 more · For: Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7 and 3 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 650 sites in all
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60aPivotal-lookingCompleted
University of LeipzigAcademic, hospital or other
NCT01497002 · 1,222 participants · Start Apr 2005 · Primary completion Jul 18, 2018
Drug: Cytarabine; human stem cells · For: Acute Myeloid Leukaemia
Sites: Leipzig, Germany
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00678327 · 1,202 participants · Start Aug 29, 2008 · Primary completion Jan 31, 2016
Drug: bleomycin sulfate; filgrastim and 9 more · For: Lymphoma
Sites: Southampton, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS, Bohlius J, Cameron DA, et al. · Eur J Cancer 2011 · Consensus Statement, Practice Guideline
- Same-day pegfilgrastim and chemotherapy.
Lokich J · Cancer Invest 2005 · Clinical Trial, Research Support, Non-U.S. Gov't
- Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial.
Li P, Chen Y, Lin Y, et al. · Ann Intern Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Jaramillo S, Benner A, Krauter J, et al. · Blood Cancer J 2017 · Comparative Study, Multicenter Study
- Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA, Greene D, Lakshmikanthan S, et al. · J Clin Pharmacol 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Accord Biopharma Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.